Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxtran-10-enhanced MRI vs Unenhanced MRI in Prostate Cancer
NCT04261777Phase 3Terminated
- Sponsor
- Saving Patients' Lives Medical B.V.
- Start
- May 2020
- Primary completion
- Jan 2025
- Modality
- Nanoparticles
- Countries
- 4
01
Overview
Phase 3, single-blind, single-arm trial of ferumoxtran-10 in prostate cancer (PCa), sponsored by Saving Patients' Lives Medical B.V. Primary endpoint: Detection of lymph node metastases by MRI scan at 42 days. Started May 2020; status: terminated.
02
Drugs
ferumoxtran-10
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04261777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261777.